Regentis Biomaterials（RGNT）株式概要Regentis Biomaterials Ltd.は再生医療企業であり、米国で組織修復ソリューションの開発と商品化を行っている。 詳細RGNT ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析過去5年間で収益は年間9.4%減少しました。 US市場と比較して、過去 3 か月間の株価の変動が非常に大きい収益が 100 万ドル未満 ( $0 )意味のある時価総額がありません ( $21M )すべてのリスクチェックを見るRGNT Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW498,716 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG498,716 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$3.93該当なし内在価値ディスカウントEst. Revenue$PastFuture-14m279k2016201920222025202620282031Revenue US$1.0Earnings US$0.2AdvancedSet Fair ValueView all narrativesRegentis Biomaterials Ltd. 競合他社Allarity TherapeuticsSymbol: NasdaqCM:ALLRMarket cap: US$20.8mNewcelXSymbol: NasdaqCM:NCELMarket cap: US$20.7mQuantum CyberSymbol: NasdaqCM:QUCYMarket cap: US$21.3mLongeveronSymbol: NasdaqCM:LGVNMarket cap: US$21.8m価格と性能株価の高値、安値、推移の概要Regentis Biomaterials過去の株価現在の株価US$3.9352週高値US$15.5052週安値US$1.23ベータ01ヶ月の変化197.73%3ヶ月変化26.77%1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化-47.60%最新ニュースお知らせ • Jun 26Regentis Biomaterials Ltd. announced that it has received $6.5 million in fundingOn June 25, 2026, Regentis Biomaterials Ltd. closed the transaction. The Placement Agent also received a $180,000 accountable expense reimbursement, a non-accountable expense allowance of $65,000 and 92,857 unregistered warrants to purchase ordinary shares. The transaction included participation from 22 investors.お知らせ • Jun 19Regentis Biomaterials Ltd. announced that it expects to receive $6.5 million in fundingRegentis Biomaterials Ltd. entered into definitive securities purchase agreements with certain accredited and institutional investors for issuance of 1,844,543 common shares at a price of $3.50 per share for gross proceeds of $6,455,900.50; and 12,600 pre-funded warrants at a price of $3.4999 per pre-funded warrant for gross proceeds of $44,098.74; for aggregate gross proceeds of $6,499,999.24 on June 17, 2026. The company will also issue ordinary warrants to purchase up to 1,857,143 ordinary shares. The pre-funded warrants have an exercise price of $0.0001 per ordinary share, are immediately exercisable upon issuance and will not expire until exercised in full. The ordinary warrants have an exercise price of $4.20 per ordinary share, are immediately exercisable upon issuance and will expire on the five-year anniversary from the date of issuance. The offering is expected to close on or about June 23, 2026. The ordinary shares, the warrants and the ordinary shares issuable upon exercise of the warrants were offered and sold pursuant to an exemption from the registration requirements of the securities act of 1933, as amended, under Section 4(a)(2) of the Securities Act and Rule 506(c) of Regulation D promulgated thereunder.お知らせ • Jun 15Regentis Biomaterials Ltd. has withdrawn its Follow-on Equity Offering in the amount of $10.000002 million.Regentis Biomaterials Ltd. has withdrawn its Follow-on Equity Offering in the amount of $10.000002 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,333,334 Price\Range: $3 Discount Per Security: $0.21お知らせ • Jun 09Regentis Biomaterials Ltd. Commences European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations AccelerateRegentis Biomaterials Ltd. announced that in the third quarter of 2026, the Company plans to commence its European surgeon training activities, as it advances preparations for the commercial rollout of GelrinC in Europe, where it has CE Mark approval. The hands-on training program is designed to train orthopedic surgeons in the use of GelrinC, providing practical experience with the implantation procedure and supporting physician readiness ahead of market launch. The first training activities are expected to take place in Milan, Italy, at Humanitas Research Hospital. Additional sessions are planned in other European markets. GelrinC is a cell-free implant for the treatment of knee cartilage lesions. The procedure utilizes a ready-to-use implant and a straightforward single-step implantation process, which takes approximately 10 minutes, and fits into the surgeon's workflow. Regentis is establishing a network of European Centers of Excellence designed to support surgeon education, clinical guidance, and knowledge sharing around cartilage repair and the use of GelrinC. These centers are intended to serve as clinical hubs where experienced orthopedic surgeons will help train and support other physicians across Europe as the technology is introduced into clinical practice. Regentis is targeting an estimated $3 billion U.S. market of 470,000 annual knee cartilage repair cases, where no approved off-the-shelf regenerative solution currently exists. Clinical data have shown approximately 100% greater pain improvement versus standard of care microfracture, alongside MRI-confirmed regeneration of near-native cartilage and durable multi-year outcomes. GelrinC has CE Mark approval in the European Union and is now being evaluated in a pivotal U.S. Food and Drug Administration study, which has completed over 50% enrollment.お知らせ • May 29Regentis Biomaterials Ltd., Annual General Meeting, Jul 02, 2026Regentis Biomaterials Ltd., Annual General Meeting, Jul 02, 2026. Location: apm house, 18 raoul wallenberg st., building d, 6th floor, ramat hachayal, tel aviv, IsraelNew Risk • May 19New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$10.00m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 9.4% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$10.00m market cap).最新情報をもっと見るRecent updatesお知らせ • Jun 26Regentis Biomaterials Ltd. announced that it has received $6.5 million in fundingOn June 25, 2026, Regentis Biomaterials Ltd. closed the transaction. The Placement Agent also received a $180,000 accountable expense reimbursement, a non-accountable expense allowance of $65,000 and 92,857 unregistered warrants to purchase ordinary shares. The transaction included participation from 22 investors.お知らせ • Jun 19Regentis Biomaterials Ltd. announced that it expects to receive $6.5 million in fundingRegentis Biomaterials Ltd. entered into definitive securities purchase agreements with certain accredited and institutional investors for issuance of 1,844,543 common shares at a price of $3.50 per share for gross proceeds of $6,455,900.50; and 12,600 pre-funded warrants at a price of $3.4999 per pre-funded warrant for gross proceeds of $44,098.74; for aggregate gross proceeds of $6,499,999.24 on June 17, 2026. The company will also issue ordinary warrants to purchase up to 1,857,143 ordinary shares. The pre-funded warrants have an exercise price of $0.0001 per ordinary share, are immediately exercisable upon issuance and will not expire until exercised in full. The ordinary warrants have an exercise price of $4.20 per ordinary share, are immediately exercisable upon issuance and will expire on the five-year anniversary from the date of issuance. The offering is expected to close on or about June 23, 2026. The ordinary shares, the warrants and the ordinary shares issuable upon exercise of the warrants were offered and sold pursuant to an exemption from the registration requirements of the securities act of 1933, as amended, under Section 4(a)(2) of the Securities Act and Rule 506(c) of Regulation D promulgated thereunder.お知らせ • Jun 15Regentis Biomaterials Ltd. has withdrawn its Follow-on Equity Offering in the amount of $10.000002 million.Regentis Biomaterials Ltd. has withdrawn its Follow-on Equity Offering in the amount of $10.000002 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,333,334 Price\Range: $3 Discount Per Security: $0.21お知らせ • Jun 09Regentis Biomaterials Ltd. Commences European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations AccelerateRegentis Biomaterials Ltd. announced that in the third quarter of 2026, the Company plans to commence its European surgeon training activities, as it advances preparations for the commercial rollout of GelrinC in Europe, where it has CE Mark approval. The hands-on training program is designed to train orthopedic surgeons in the use of GelrinC, providing practical experience with the implantation procedure and supporting physician readiness ahead of market launch. The first training activities are expected to take place in Milan, Italy, at Humanitas Research Hospital. Additional sessions are planned in other European markets. GelrinC is a cell-free implant for the treatment of knee cartilage lesions. The procedure utilizes a ready-to-use implant and a straightforward single-step implantation process, which takes approximately 10 minutes, and fits into the surgeon's workflow. Regentis is establishing a network of European Centers of Excellence designed to support surgeon education, clinical guidance, and knowledge sharing around cartilage repair and the use of GelrinC. These centers are intended to serve as clinical hubs where experienced orthopedic surgeons will help train and support other physicians across Europe as the technology is introduced into clinical practice. Regentis is targeting an estimated $3 billion U.S. market of 470,000 annual knee cartilage repair cases, where no approved off-the-shelf regenerative solution currently exists. Clinical data have shown approximately 100% greater pain improvement versus standard of care microfracture, alongside MRI-confirmed regeneration of near-native cartilage and durable multi-year outcomes. GelrinC has CE Mark approval in the European Union and is now being evaluated in a pivotal U.S. Food and Drug Administration study, which has completed over 50% enrollment.お知らせ • May 29Regentis Biomaterials Ltd., Annual General Meeting, Jul 02, 2026Regentis Biomaterials Ltd., Annual General Meeting, Jul 02, 2026. Location: apm house, 18 raoul wallenberg st., building d, 6th floor, ramat hachayal, tel aviv, IsraelNew Risk • May 19New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$10.00m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 9.4% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$10.00m market cap).お知らせ • May 03Regentis Biomaterials Ltd. has filed a Follow-on Equity Offering in the amount of $10.000002 million.Regentis Biomaterials Ltd. has filed a Follow-on Equity Offering in the amount of $10.000002 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,333,334 Price\Range: $3 Discount Per Security: $0.21New Risk • Feb 26New major risk - Revenue and earnings growthEarnings have declined by 5.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 5.7% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$20.7m market cap).お知らせ • Feb 04+ 1 more updateRegentis Biomaterials Ltd. Announces the Appointment of Ori Gon as Chief Financial Officer, Effective February 4, 2026Regentis Biomaterials Ltd. announced the appointment of Ori Gon as Chief Financial Officer, effective February 4, 2026. Mr. Gon will lead the Company's commercial and business development activities, as well as its financial strategy, planning, and reporting. Mr. Gon joins Regentis at a pivotal time as GelrinC®, the Company's proprietary hydrogel implant for knee cartilage repair, advances towards commercial launch in Europe following CE Mark approval and is being evaluated in a pivotal Phase III FDA clinical trial in the United States. Mr. Gon brings over 15 years of financial leadership experience across public and private enterprises and medical technology. Most recently, he served as CFO at Tactile Mobility, a sensing and data analytics company focused on advanced automotive and mobility applications. Prior to that, he held senior financial leadership roles at ReWalk Robotics Inc., now Nasdaq-listed Lifeward Ltd., a pioneer in wearable robotic exoskeletons for individuals with lower limb disabilities, where he served as CFO and Corporate Controller. Earlier in his career, he was Controller at On Track Innovations Ltd., a Nasdaq- and Neuer Markt-listed fintech company. He began his professional career as an auditor at KPMG Israel. Mr. Gon has led multiple secondary public offerings and financing transactions across various structures, raising over $150 million in aggregate capital. He is a Certified Public Accountant (CPA) in Israel.お知らせ • Jan 21Regentis Biomaterials Ltd. Announces New Long-Term Imaging Data from Its Successfully Completed European Clinical Trial of GelrinCRegentis Biomaterials Ltd. announced new long-term imaging data from its successfully completed European clinical trial of GelrinC, demonstrating that regenerated cartilage exhibits internal structural organization closely resembling healthy, native hyaline cartilage. The analysis was conducted by Prof. Siegfried Trattnig of Vienna University and his colleagues, global leaders in cartilage MRI imaging, using validated methodologies accepted by both U.S. FDA and Europe's EMA regulators, further strengthening the translational and regulatory relevance of the findings. As an innovative regenerative medical product, GelrinC offers an unprecedented solution that gives surgeons and payers an off-the-shelf, ready to use, simple to perform, reliable, and cost-effective procedure that provides patients with a single, 10-minute procedure, faster recovery, sustained pain relief, and functional improvement for more than 4 years, based on clinical study results to date. GelrinC has CE Mark approval in the European Union and is now being evaluated in a pivotal U.S. Food and Drug Administration (FDA) study, which has completed over 50% enrollment.お知らせ • Jan 08+ 1 more updateRegentis Biomaterials Ltd. Gelrinc Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART EvaluationRegentis Biomaterials Ltd. announced publication of long-term follow-up results from its successfully concluded Phase II clinical trial of GelrinC in the peer-reviewed journal Cartilage. The study, led by Prof. Siegfried Trattnig of Vienna University and colleagues, reports strong radiologic evidence of durable cartilage regeneration at 24 months. Regentis is the first company to extensively use MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue), a validated MRI-based quantitative measure of cartilage quantity and quality as a secondary endpoint in a clinical study, and to have the U.S. Food and Drug Administration’s (FDA) acceptance of this approach. In contrast to the predominantly subjective clinical endpoints commonly used in cartilage repair studies, Regentis deliberately selected objective, imaging-based endpoints as a rigorous measure of structural repair from the outset. Regentis is unique in having predefined MOCART as a prospective imaging and primary endpoint built into the protocol from day one, and in having the MOCART assessments conducted by the Vienna University-based team that developed the method which is widely regarded as the gold standard. As such, Regentis is advancing what it believes is a more rigorous standard for assessing cartilage regeneration by emphasizing objective, quantitative structural outcomes alongside the current standard of care KOOS (Knee Injury and Osteoarthritis Outcome Score) which is a questionnaire-based patient-reported measure of pain. In practice, these results mean that two years after treatment, the repaired cartilage appears very close to normal, healthy cartilage based on objective MRI assessment. Importantly, the imaging shows ongoing tissue maturation over time, supporting the durability of the repair. GelrinC is currently being evaluated in a pivotal Phase III U.S. Food and Drug Administration investigational device exemption (IDE) study designed to support a future premarket approval (PMA) submission, with 80 patients and two-year follow-up as part of the core study design. Regentis has achieved over 50% enrollment.お知らせ • Dec 04Regentis Biomaterials Ltd. has completed an IPO in the amount of $10 million.Regentis Biomaterials Ltd. has completed an IPO in the amount of $10 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,250,000 Price\Range: $8 Discount Per Security: $0.56 Transaction Features: Sponsor Backed OfferingNew Risk • Nov 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$1.78m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$987k free cash flow). Shares are highly illiquid. Negative equity (-US$9.2m). Revenue is less than US$1m. Market cap is less than US$10m (US$1.78m market cap).Board Change • Sep 11Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Keith Valentine was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.株主還元RGNTUS BiotechsUS 市場7D4.2%4.1%1.6%1Yn/a41.1%18.6%株主還元を見る業界別リターン: RGNTがUS Biotechs業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: RGNT US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is RGNT's price volatile compared to industry and market?RGNT volatilityRGNT Average Weekly Movement155.0%Biotechs Industry Average Movement10.3%Market Average Movement7.3%10% most volatile stocks in US Market16.7%10% least volatile stocks in US Market3.2%安定した株価: RGNTの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: RGNTの 週次ボラティリティ は、過去 1 年間で103%から155%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト2004n/aEhud Gellerwww.regentis.co.il再生医療企業であるRegentis Biomaterials Ltd.は、米国で組織修復ソリューションの開発と商業化を行う。同社はポリエチレングリコールジアクリレートと変性フィブリノーゲンのハイドロゲルマトリックスをベースとしたプラットフォームであるGelrinを提供し、損傷または疾患組織の治療と再生を行う。同社は2004年に法人化され、イスラエルのヘルズリヤを拠点としている。もっと見るRegentis Biomaterials Ltd. 基礎のまとめRegentis Biomaterials の収益と売上を時価総額と比較するとどうか。RGNT 基礎統計学時価総額US$20.87m収益（TTM）-US$13.69m売上高(TTM)n/a0.0xP/Sレシオ-1.5xPER（株価収益率RGNT は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計RGNT 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$13.69m収益-US$13.69m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-2.64グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率25.2%RGNT の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/06 01:39終値2026/07/06 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Regentis Biomaterials Ltd. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Ashok KumarThinkEquity LLC
お知らせ • Jun 26Regentis Biomaterials Ltd. announced that it has received $6.5 million in fundingOn June 25, 2026, Regentis Biomaterials Ltd. closed the transaction. The Placement Agent also received a $180,000 accountable expense reimbursement, a non-accountable expense allowance of $65,000 and 92,857 unregistered warrants to purchase ordinary shares. The transaction included participation from 22 investors.
お知らせ • Jun 19Regentis Biomaterials Ltd. announced that it expects to receive $6.5 million in fundingRegentis Biomaterials Ltd. entered into definitive securities purchase agreements with certain accredited and institutional investors for issuance of 1,844,543 common shares at a price of $3.50 per share for gross proceeds of $6,455,900.50; and 12,600 pre-funded warrants at a price of $3.4999 per pre-funded warrant for gross proceeds of $44,098.74; for aggregate gross proceeds of $6,499,999.24 on June 17, 2026. The company will also issue ordinary warrants to purchase up to 1,857,143 ordinary shares. The pre-funded warrants have an exercise price of $0.0001 per ordinary share, are immediately exercisable upon issuance and will not expire until exercised in full. The ordinary warrants have an exercise price of $4.20 per ordinary share, are immediately exercisable upon issuance and will expire on the five-year anniversary from the date of issuance. The offering is expected to close on or about June 23, 2026. The ordinary shares, the warrants and the ordinary shares issuable upon exercise of the warrants were offered and sold pursuant to an exemption from the registration requirements of the securities act of 1933, as amended, under Section 4(a)(2) of the Securities Act and Rule 506(c) of Regulation D promulgated thereunder.
お知らせ • Jun 15Regentis Biomaterials Ltd. has withdrawn its Follow-on Equity Offering in the amount of $10.000002 million.Regentis Biomaterials Ltd. has withdrawn its Follow-on Equity Offering in the amount of $10.000002 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,333,334 Price\Range: $3 Discount Per Security: $0.21
お知らせ • Jun 09Regentis Biomaterials Ltd. Commences European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations AccelerateRegentis Biomaterials Ltd. announced that in the third quarter of 2026, the Company plans to commence its European surgeon training activities, as it advances preparations for the commercial rollout of GelrinC in Europe, where it has CE Mark approval. The hands-on training program is designed to train orthopedic surgeons in the use of GelrinC, providing practical experience with the implantation procedure and supporting physician readiness ahead of market launch. The first training activities are expected to take place in Milan, Italy, at Humanitas Research Hospital. Additional sessions are planned in other European markets. GelrinC is a cell-free implant for the treatment of knee cartilage lesions. The procedure utilizes a ready-to-use implant and a straightforward single-step implantation process, which takes approximately 10 minutes, and fits into the surgeon's workflow. Regentis is establishing a network of European Centers of Excellence designed to support surgeon education, clinical guidance, and knowledge sharing around cartilage repair and the use of GelrinC. These centers are intended to serve as clinical hubs where experienced orthopedic surgeons will help train and support other physicians across Europe as the technology is introduced into clinical practice. Regentis is targeting an estimated $3 billion U.S. market of 470,000 annual knee cartilage repair cases, where no approved off-the-shelf regenerative solution currently exists. Clinical data have shown approximately 100% greater pain improvement versus standard of care microfracture, alongside MRI-confirmed regeneration of near-native cartilage and durable multi-year outcomes. GelrinC has CE Mark approval in the European Union and is now being evaluated in a pivotal U.S. Food and Drug Administration study, which has completed over 50% enrollment.
お知らせ • May 29Regentis Biomaterials Ltd., Annual General Meeting, Jul 02, 2026Regentis Biomaterials Ltd., Annual General Meeting, Jul 02, 2026. Location: apm house, 18 raoul wallenberg st., building d, 6th floor, ramat hachayal, tel aviv, Israel
New Risk • May 19New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$10.00m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 9.4% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$10.00m market cap).
お知らせ • Jun 26Regentis Biomaterials Ltd. announced that it has received $6.5 million in fundingOn June 25, 2026, Regentis Biomaterials Ltd. closed the transaction. The Placement Agent also received a $180,000 accountable expense reimbursement, a non-accountable expense allowance of $65,000 and 92,857 unregistered warrants to purchase ordinary shares. The transaction included participation from 22 investors.
お知らせ • Jun 19Regentis Biomaterials Ltd. announced that it expects to receive $6.5 million in fundingRegentis Biomaterials Ltd. entered into definitive securities purchase agreements with certain accredited and institutional investors for issuance of 1,844,543 common shares at a price of $3.50 per share for gross proceeds of $6,455,900.50; and 12,600 pre-funded warrants at a price of $3.4999 per pre-funded warrant for gross proceeds of $44,098.74; for aggregate gross proceeds of $6,499,999.24 on June 17, 2026. The company will also issue ordinary warrants to purchase up to 1,857,143 ordinary shares. The pre-funded warrants have an exercise price of $0.0001 per ordinary share, are immediately exercisable upon issuance and will not expire until exercised in full. The ordinary warrants have an exercise price of $4.20 per ordinary share, are immediately exercisable upon issuance and will expire on the five-year anniversary from the date of issuance. The offering is expected to close on or about June 23, 2026. The ordinary shares, the warrants and the ordinary shares issuable upon exercise of the warrants were offered and sold pursuant to an exemption from the registration requirements of the securities act of 1933, as amended, under Section 4(a)(2) of the Securities Act and Rule 506(c) of Regulation D promulgated thereunder.
お知らせ • Jun 15Regentis Biomaterials Ltd. has withdrawn its Follow-on Equity Offering in the amount of $10.000002 million.Regentis Biomaterials Ltd. has withdrawn its Follow-on Equity Offering in the amount of $10.000002 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,333,334 Price\Range: $3 Discount Per Security: $0.21
お知らせ • Jun 09Regentis Biomaterials Ltd. Commences European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations AccelerateRegentis Biomaterials Ltd. announced that in the third quarter of 2026, the Company plans to commence its European surgeon training activities, as it advances preparations for the commercial rollout of GelrinC in Europe, where it has CE Mark approval. The hands-on training program is designed to train orthopedic surgeons in the use of GelrinC, providing practical experience with the implantation procedure and supporting physician readiness ahead of market launch. The first training activities are expected to take place in Milan, Italy, at Humanitas Research Hospital. Additional sessions are planned in other European markets. GelrinC is a cell-free implant for the treatment of knee cartilage lesions. The procedure utilizes a ready-to-use implant and a straightforward single-step implantation process, which takes approximately 10 minutes, and fits into the surgeon's workflow. Regentis is establishing a network of European Centers of Excellence designed to support surgeon education, clinical guidance, and knowledge sharing around cartilage repair and the use of GelrinC. These centers are intended to serve as clinical hubs where experienced orthopedic surgeons will help train and support other physicians across Europe as the technology is introduced into clinical practice. Regentis is targeting an estimated $3 billion U.S. market of 470,000 annual knee cartilage repair cases, where no approved off-the-shelf regenerative solution currently exists. Clinical data have shown approximately 100% greater pain improvement versus standard of care microfracture, alongside MRI-confirmed regeneration of near-native cartilage and durable multi-year outcomes. GelrinC has CE Mark approval in the European Union and is now being evaluated in a pivotal U.S. Food and Drug Administration study, which has completed over 50% enrollment.
お知らせ • May 29Regentis Biomaterials Ltd., Annual General Meeting, Jul 02, 2026Regentis Biomaterials Ltd., Annual General Meeting, Jul 02, 2026. Location: apm house, 18 raoul wallenberg st., building d, 6th floor, ramat hachayal, tel aviv, Israel
New Risk • May 19New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$10.00m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 9.4% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$10.00m market cap).
お知らせ • May 03Regentis Biomaterials Ltd. has filed a Follow-on Equity Offering in the amount of $10.000002 million.Regentis Biomaterials Ltd. has filed a Follow-on Equity Offering in the amount of $10.000002 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,333,334 Price\Range: $3 Discount Per Security: $0.21
New Risk • Feb 26New major risk - Revenue and earnings growthEarnings have declined by 5.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 5.7% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$20.7m market cap).
お知らせ • Feb 04+ 1 more updateRegentis Biomaterials Ltd. Announces the Appointment of Ori Gon as Chief Financial Officer, Effective February 4, 2026Regentis Biomaterials Ltd. announced the appointment of Ori Gon as Chief Financial Officer, effective February 4, 2026. Mr. Gon will lead the Company's commercial and business development activities, as well as its financial strategy, planning, and reporting. Mr. Gon joins Regentis at a pivotal time as GelrinC®, the Company's proprietary hydrogel implant for knee cartilage repair, advances towards commercial launch in Europe following CE Mark approval and is being evaluated in a pivotal Phase III FDA clinical trial in the United States. Mr. Gon brings over 15 years of financial leadership experience across public and private enterprises and medical technology. Most recently, he served as CFO at Tactile Mobility, a sensing and data analytics company focused on advanced automotive and mobility applications. Prior to that, he held senior financial leadership roles at ReWalk Robotics Inc., now Nasdaq-listed Lifeward Ltd., a pioneer in wearable robotic exoskeletons for individuals with lower limb disabilities, where he served as CFO and Corporate Controller. Earlier in his career, he was Controller at On Track Innovations Ltd., a Nasdaq- and Neuer Markt-listed fintech company. He began his professional career as an auditor at KPMG Israel. Mr. Gon has led multiple secondary public offerings and financing transactions across various structures, raising over $150 million in aggregate capital. He is a Certified Public Accountant (CPA) in Israel.
お知らせ • Jan 21Regentis Biomaterials Ltd. Announces New Long-Term Imaging Data from Its Successfully Completed European Clinical Trial of GelrinCRegentis Biomaterials Ltd. announced new long-term imaging data from its successfully completed European clinical trial of GelrinC, demonstrating that regenerated cartilage exhibits internal structural organization closely resembling healthy, native hyaline cartilage. The analysis was conducted by Prof. Siegfried Trattnig of Vienna University and his colleagues, global leaders in cartilage MRI imaging, using validated methodologies accepted by both U.S. FDA and Europe's EMA regulators, further strengthening the translational and regulatory relevance of the findings. As an innovative regenerative medical product, GelrinC offers an unprecedented solution that gives surgeons and payers an off-the-shelf, ready to use, simple to perform, reliable, and cost-effective procedure that provides patients with a single, 10-minute procedure, faster recovery, sustained pain relief, and functional improvement for more than 4 years, based on clinical study results to date. GelrinC has CE Mark approval in the European Union and is now being evaluated in a pivotal U.S. Food and Drug Administration (FDA) study, which has completed over 50% enrollment.
お知らせ • Jan 08+ 1 more updateRegentis Biomaterials Ltd. Gelrinc Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART EvaluationRegentis Biomaterials Ltd. announced publication of long-term follow-up results from its successfully concluded Phase II clinical trial of GelrinC in the peer-reviewed journal Cartilage. The study, led by Prof. Siegfried Trattnig of Vienna University and colleagues, reports strong radiologic evidence of durable cartilage regeneration at 24 months. Regentis is the first company to extensively use MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue), a validated MRI-based quantitative measure of cartilage quantity and quality as a secondary endpoint in a clinical study, and to have the U.S. Food and Drug Administration’s (FDA) acceptance of this approach. In contrast to the predominantly subjective clinical endpoints commonly used in cartilage repair studies, Regentis deliberately selected objective, imaging-based endpoints as a rigorous measure of structural repair from the outset. Regentis is unique in having predefined MOCART as a prospective imaging and primary endpoint built into the protocol from day one, and in having the MOCART assessments conducted by the Vienna University-based team that developed the method which is widely regarded as the gold standard. As such, Regentis is advancing what it believes is a more rigorous standard for assessing cartilage regeneration by emphasizing objective, quantitative structural outcomes alongside the current standard of care KOOS (Knee Injury and Osteoarthritis Outcome Score) which is a questionnaire-based patient-reported measure of pain. In practice, these results mean that two years after treatment, the repaired cartilage appears very close to normal, healthy cartilage based on objective MRI assessment. Importantly, the imaging shows ongoing tissue maturation over time, supporting the durability of the repair. GelrinC is currently being evaluated in a pivotal Phase III U.S. Food and Drug Administration investigational device exemption (IDE) study designed to support a future premarket approval (PMA) submission, with 80 patients and two-year follow-up as part of the core study design. Regentis has achieved over 50% enrollment.
お知らせ • Dec 04Regentis Biomaterials Ltd. has completed an IPO in the amount of $10 million.Regentis Biomaterials Ltd. has completed an IPO in the amount of $10 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,250,000 Price\Range: $8 Discount Per Security: $0.56 Transaction Features: Sponsor Backed Offering
New Risk • Nov 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$1.78m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$987k free cash flow). Shares are highly illiquid. Negative equity (-US$9.2m). Revenue is less than US$1m. Market cap is less than US$10m (US$1.78m market cap).
Board Change • Sep 11Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Keith Valentine was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
